Literature DB >> 11069628

The extracellular domain of BPAG2 has a loop structure in the carboxy terminal flexible tail in vivo.

S Nonaka1, A Ishiko, T Masunaga, M Akiyama, K Owaribe, H Shimizu, T Nishikawa.   

Abstract

The 180 kDa bullous pemphigoid antigen is a hemidesmosome-associated transmembranous protein with a molecule length estimated to be 190-230 nm, which is much longer than the transverse length of the lamina lucida and lamina densa. The purpose of this study was to clarify the precise in vivo structure of the 180 kDa bullous pemphigoid antigen in normal human skin. We used three monoclonal antibodies directed to (i) the intracellular globular head of the 180 kDa bullous pemphigoid antigen, (ii) the mid-portion of the flexible tail of the antigen, corresponding approximately to amino acids 1000-1320, and (iii) the carboxyl terminal end, corresponding approximately to amino acids 1320-1500 of the antigen. Using low temperature postembedding immunoelectron microscopy, we quantitated the distribution of immunogold labeling of these monoclonal antibodies in normal human skin. The results showed that the monoclonal antibodies (i) bound to the intracellular portion of the hemidesmosome at a mean distance of 20 nm from the plasma membrane, (ii) bound to the lamina densa beneath the hemidesmosome at a mean distance of 65 nm from the plasma membrane, and (iii) bound to the lamina densa-lamina lucida interface at a mean distance of 39 nm from the plasma membrane. Considering the reported size of the 180 kDa bullous pemphigoid antigen, our results indicate that the extracellular domain of the antigen has at least one loop structure in the lamina densa in vivo. This unique structure of the antigen is thought to contribute to dermo- epidermal adhesion by intertwining with other basement membrane components.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069628     DOI: 10.1046/j.1523-1747.2000.00136.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  The NC16A domain of collagen XVII plays a role in triple helix assembly and stability.

Authors:  Françoise Van den Bergh; Chang-Ling Fu; Monica Olague-Marchan; George J Giudice
Journal:  Biochem Biophys Res Commun       Date:  2006-10-05       Impact factor: 3.575

2.  The pathophysiology of autoimmune blistering diseases.

Authors:  Kim B Yancey
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

3.  Itch, eosinophils, and autoimmunity: a novel murine model of bullous pemphigoid.

Authors:  Kim B Yancey
Journal:  J Invest Dermatol       Date:  2015-05       Impact factor: 8.551

4.  Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice.

Authors:  Edit B Olasz; Jooyoung Roh; Carole L Yee; Ken Arita; Masashi Akiyama; Hiroshi Shimizu; Jonathan C Vogel; Kim B Yancey
Journal:  J Invest Dermatol       Date:  2007-07-26       Impact factor: 8.551

5.  Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen.

Authors:  Gang Wang; Hideyuki Ujiie; Akihiko Shibaki; Wataru Nishie; Yasuki Tateishi; Kazuhiro Kikuchi; Qiang Li; James R McMillan; Hiroshi Morioka; Daisuke Sawamura; Hideki Nakamura; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

6.  Keratinocytes from patients lacking collagen XVII display a migratory phenotype.

Authors:  Kaisa Tasanen; Lucy Tunggal; Gretel Chometon; Leena Bruckner-Tuderman; Monique Aumailley
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

7.  Bullous Pemphigoid IgG Induces Cell Dysfunction and Enhances the Motility of Epidermal Keratinocytes via Rac1/Proteasome Activation.

Authors:  Duerna Tie; Xia Da; Ken Natsuga; Nanako Yamada; Osamu Yamamoto; Eishin Morita
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

Review 8.  BP180/Collagen XVII: A Molecular View.

Authors:  Jussi Tuusa; Nina Kokkonen; Kaisa Tasanen
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.